Researchers Find Early Driver of Prostate Cancer Aggressiveness

Researchers at the University of Michigan Rogel Cancer Center have identified a gene, PROX1, that may play a key role in making certain prostate cancers more difficult to treat. These aggressive cancers often become resistant to standard therapies that target androgen receptor hormones. The team also discovered that a class of FDA-approved drugs can reduce PROX1 levels and effectively kill these treatment-resistant cancer cells. Read the full article to learn how this breakthrough could pave the way for new patient treatment options.